Literature DB >> 20708647

mRNA transfection of cervical carcinoma and mesenchymal stem cells mediated by cationic carriers.

Joanna Rejman1, Geertrui Tavernier, Neda Bavarsad, Joseph Demeester, Stefaan C De Smedt.   

Abstract

Messenger RNA encoding luciferase (mLUC) was complexed to the cationic lipids Lipofectamine or DOTAP/DOPE, and to the cationic polymer linear poly(ethyleneimine) (linPEI). The complexes were incubated with HeLa cells and luciferase expression was assessed. The type of non-viral carrier used determined the extent and duration of protein expression. Maximal duration of mRNA expression was about 9 days for Lipofectamine complexes, i.e. not very much shorter than with pDNA polyplexes. Interestingly, luciferase activity was already detected 30 min after adding the mRNA complexes to the cells, independent on the type of carrier. We also assessed the proportion of cells that become transfected by means of transfection with an mRNA encoding GFP. For both cationic lipids transfection with mRNA yielded a substantially larger fraction of transfected cells (more than 80%) than transfection with pDNA (40%). In addition we tested the carriers for their ability to mediate delivery of mRNA encoding CXCR4 into mesenchymal stem cells. The fraction of CXCR4-positive cells obtained with the mRNA-cationic lipid complexes was around 80%, as compared to 40% for the linPEI polyplexes. Our results demonstrate that the advantage of the use of mRNA over that of pDNA may under certain conditions outweigh the disadvantage of the somewhat shorter expression period.
Copyright © 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20708647     DOI: 10.1016/j.jconrel.2010.07.124

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  27 in total

Review 1.  Advances in Biomaterials for Drug Delivery.

Authors:  Owen S Fenton; Katy N Olafson; Padmini S Pillai; Michael J Mitchell; Robert Langer
Journal:  Adv Mater       Date:  2018-05-07       Impact factor: 30.849

2.  Inorganic nanovectors for nucleic acid delivery.

Authors:  Sandhya Pranatharthiharan; Mitesh D Patel; Anisha A D'Souza; Padma V Devarajan
Journal:  Drug Deliv Transl Res       Date:  2013-10       Impact factor: 4.617

Review 3.  Nanotechnologies in delivery of mRNA therapeutics using nonviral vector-based delivery systems.

Authors:  S Guan; J Rosenecker
Journal:  Gene Ther       Date:  2017-01-17       Impact factor: 5.250

4.  Charge-altering releasable transporters (CARTs) for the delivery and release of mRNA in living animals.

Authors:  Colin J McKinlay; Jessica R Vargas; Timothy R Blake; Jonathan W Hardy; Masamitsu Kanada; Christopher H Contag; Paul A Wender; Robert M Waymouth
Journal:  Proc Natl Acad Sci U S A       Date:  2017-01-09       Impact factor: 11.205

5.  Zinc Finger Nucleases: Tailor-made for Gene Therapy.

Authors:  S-T Chou; Qixin Leng; A J Mixson
Journal:  Drugs Future       Date:  2012-03-01       Impact factor: 0.148

6.  Multifunctional triblock copolymers for intracellular messenger RNA delivery.

Authors:  Connie Cheng; Anthony J Convertine; Patrick S Stayton; James D Bryers
Journal:  Biomaterials       Date:  2012-07-09       Impact factor: 12.479

Review 7.  Engineering mesenchymal stem cells for regenerative medicine and drug delivery.

Authors:  Ji Sun Park; Smruthi Suryaprakash; Yeh-Hsing Lao; Kam W Leong
Journal:  Methods       Date:  2015-03-11       Impact factor: 3.608

8.  Biomaterials for mRNA delivery.

Authors:  Mohammad Ariful Islam; Emma K G Reesor; Yingjie Xu; Harshal R Zope; Bruce R Zetter; Jinjun Shi
Journal:  Biomater Sci       Date:  2015-08-17       Impact factor: 6.843

9.  Injectable Biodegradable Chitosan-Alginate 3D Porous Gel Scaffold for mRNA Vaccine Delivery.

Authors:  Jingxuan Yan; Ruying Chen; Hong Zhang; James D Bryers
Journal:  Macromol Biosci       Date:  2018-11-16       Impact factor: 4.979

10.  In vivo messenger RNA introduction into the central nervous system using polyplex nanomicelle.

Authors:  Satoshi Uchida; Keiji Itaka; Hirokuni Uchida; Kentaro Hayakawa; Toru Ogata; Takehiko Ishii; Shigeto Fukushima; Kensuke Osada; Kazunori Kataoka
Journal:  PLoS One       Date:  2013-02-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.